Nivolumab plus ipilimumab is another alternative for advanced NSCLC with PD-L1 TPS ≥ 1%; however, in the CheckMate-227 trial, this combination demonstrated a superior survival rate compared with chemotherapy, irrespective of PD-L1 expression [20]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.